Critical Contrast: Bright Minds Biosciences (NASDAQ:DRUG) vs. IDEAYA Biosciences (NASDAQ:IDYA)

Bright Minds Biosciences (NASDAQ:DRUG) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Insider & Institutional Ownership

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Bright Minds Biosciences and IDEAYA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
IDEAYA Biosciences	N/A	-14.24%	-13.09%

Risk and Volatility

Bright Minds Biosciences has a beta of -5.53, meaning that its share price is 653% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Bright Minds Biosciences and IDEAYA Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0	1	6	0	2.86
IDEAYA Biosciences	1	1	15	0	2.82

Bright Minds Biosciences presently has a consensus price target of $143.83, indicating a potential upside of 77.53%. IDEAYA Biosciences has a consensus price target of $50.69, indicating a potential upside of 75.15%. Given Bright Minds Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than IDEAYA Biosciences.

Valuation and Earnings

This table compares Bright Minds Biosciences and IDEAYA Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74 million	($2.44)	-33.20
IDEAYA Biosciences	$225.27 million	11.29	-$113.70 million	($1.60)	-18.09

Bright Minds Biosciences has higher earnings, but lower revenue than IDEAYA Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

IDEAYA Biosciences beats Bright Minds Biosciences on 8 of the 12 factors compared between the two stocks.

About Bright Minds Biosciences

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.